


Medicamen Biotech Limited

Q2, 2024



Our Journey till date - Medicamen

2017-2019

- ▶ Initiate modernisation of Bhiwadi plant (India) compatible to EU standards
- ▶ Appointed new managerial team at corporate office, manufacturing plant, and R&D center.

2020 - 2022

- ▶ Opened dedicated Oncology Formulation Plant at Haridwar (India)
- ▶ Completed capacity expansion at Bhiwadi plant
- ▶ Formed new distribution subsidiary for India, Medicamen Lifesciences, with team of 110 team, for

2023 – till date

- ▶ Granted US-FDA approval for Oncology formulation plant at Haridwar
- ▶ Granted EU GMP (from Greece) approval for Bhiwadi plant
- ▶ Applied for desktop approval in Australia
- ▶ Filed first ANDA with US-FDA for Bortezomib injection 3.5mg

Growth Drivers Unlocking Future Value

Oncology Segment

- ▶ Introduced a specialized oncology brand for Indian market - Vivo Oncology
- ▶ Launched 12 products and successfully penetrated 16 cities across Northern and Western India
- ▶ Supplying to top institutions like Tata Memorial (Mumbai), Rajiv Gandhi Cancer Institute (Delhi), AIIMS, Max, Fortis.

Global Expansion

- ▶ Implementing a dual-distribution strategy leveraging internal sales with strategic partnerships
- ▶ To launch 10 non-oncology formulations for European Union market
- ▶ Filed first ANDA with US-FDA for Bortezomib injection

Domestic Market

- ▶ Launched Medicamen Lifesciences, a subsidiary focused on marketing Cardio-Vascular and diabetic (CVD) and pain management products in Indian market
- ▶ Strong presence across Indian cities with growing distribution network nationwide

30

Senior personnel

53

SKUs

160

Products registered

280

Products under registration and filing

100

Employee team

74

SKUs

Global Footprint

100+ products are currently available in over **25** countries...

... approval of ongoing registrations and filings will unlock newer markets and expand product offerings

Latin America

- ▶ Brazil
- ▶ Cuba
- ▶ Dominic Republic
- ▶ Curacao
- ▶ Jamaica
- ▶ Haiti

Asia Pacific*

- ▶ Afghanistan
- ▶ Bhutan
- ▶ Cambodia
- ▶ Philippines
- ▶ Myanmar
- ▶ Nepal
- ▶ Sri Lanka
- ▶ Australia
- ▶ Kyrgyzstan
- ▶ Tajikistan

Africa


- ▶ Cameroon
- ▶ Congo
- ▶ Ethiopia
- ▶ Ghana
- ▶ Ivory cost
- ▶ Kenya
- ▶ Malawi
- ▶ Namibia
- ▶ Nigeria
- ▶ South Sudan
- ▶ Uganda
- ▶ Zambia
- ▶ Zimbabwe



Filed first ANDA with US-FDA for Bortezomib injection 3.5mg



7 products developed and filed
4 products under registration and filing
4 products under development in R&D



Products registration received
7 in Mali
5 in Zimbabwe

Products filed
40 in Ethiopia
20 in Mozambique
50 in Ghana
8 in Namibia
40 Cameroon




Prepared to file 5 dossiers in Australia pending desktop approval confirmation

Manufacturing facilities: Three cutting-edge plants developing finished dosage forms

Bhiwadi, Rajasthan

- ▶ A six-block contemporary facility for general formulations
- ▶ Dedicated research and development block for formulation development
- ▶ Distinct block to store finished goods
- ▶ 210,000 sq. feet area

EU GMP (Greece) approved facility
WHO GMP certified
ISO certified



Haridwar Unit I, Uttarakhand (General)

- ▶ Focused on general formulations - diverse finished dose forms
- ▶ Houses a well-developed quality control (QC) lab
- ▶ 32,000 sq. feet area

WHO GMP certified

Haridwar Unit II, Uttarakhand (Oncology)

- ▶ State-of-the-art facility dedicated to Oncology formulations – lyophilized and ready to use formulations
- ▶ 35,000 sq. feet area

US-FDA approved facility
WHO GMP certified



Bhiwadi



Haridwar I



Haridwar II



Targeted marketing investments

We are strategically reinvesting our cash flow to drive long-term growth by expanding our marketing efforts.

This includes launching a domestic distribution subsidiary with a team of over 100 employees and building a dedicated oncology brand with more than 30 experts, all designed to position us for sustained success and leadership in the market.

Product/ Dossier Registration Investments

Our expanding product registrations and dossier submissions, while capital intensive, will unlock new opportunities in more regulated markets.

While African clients currently account for 70% of our sales, we are expanding into European, U.S. and Middle East markets in the medium term, which will significantly drive the growth.



Medicamen Biotech Limited

Registered Office:

1506, Chiranjiv Tower, 43 Nehru Place, New Delhi- 110019

Phone: 011-47589500 (30 Lines)

Fax: 011-26213081

E-mail: vk@medicamen.com

Website: www.medicamen.com

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, cash flow projections, our exposure to market risks as well as other risks. Medicamen Biotech Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.